Alnylam Pharmaceuticals Inc

Financials

İşletme faaliyetlerinden elde edilen nakit -94.66 M-118.31 M153.73 M325.11 M163.56 M 524.08 M Yatırım faaliyetlerinden elde edilen nakit -52.91 M113.77 M-141.38 M501.11 M-37.17 M 436.33 M Finansman faaliyetlerinden elde edilen nakit 31 M44.08 M53.76 M-448.35 M45.32 M -305.19 M Free cash flow -103.76 M-127.28 M139.44 M312.97 M140.26 M 465.38 M

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

ALNY

Financials

Alnylam Pharmaceuticals Inc

Haberler

Leaderboard Trimmed, But Cloudflare, Caterpillar Among 5 Stocks To Watch

Alnylam ACC konferansında kardiyovasküler veri sundu

Repligen (RGEN) Down 13.5% Since Last Earnings Report: Can It Rebound?

H.C. Wainwright, Alnylam hissesi için al önerisini korudu, hedef 510 dolar

Stifel, Alnylam hissesi için Al tavsiyesini korudu, hedef 444 dolar

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR Franchise Transcript

BofA Securities, Alnylam için 460 dolarlık hedefi korudu

Morgan Stanley, Alnylam hissesi için 360 dolar hedefini tekrarladı

Alnylam, ATTR-CM teşhisi için Viz.ai ve AHA ile ortaklık kurdu

Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?

Jefferies, değerleme endişeleriyle Alnylam hissesini düşürdü

Jefferies downgrades Alnylam stock rating on valuation concerns